PTSD and Psychedelics: MDMA Therapy Review

TL;DR

PTSD Review: Chapter reviews psychedelic-assisted therapies for post-traumatic stress disorder (PTSD), focusing on MDMA-assisted therapy.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)[[2]](https://www.sciencedirect.com/bookseries/international-review-of-neurobiology/vol/181/suppl/C)
FDA Rejection: FDA rejected MDMA therapy approval in 2024 due to unblinding and expectancy effects despite 2017 breakthrough status.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
Research Promise: MDMA trials show sustained symptom reductions for treatment-resistant patients, but more studies needed.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

The story at a glance

This chapter in International Review of Neurobiology Volume 181, Psychedelics in Psychiatry, examines clinical research on psychedelics for PTSD, led by authors Tijmen Bostoen, Stephan Tap, Joost Breeksema, and Robert Schoevers from Dutch research centers. It highlights MDMA-assisted therapy's progress and setbacks, including the FDA's 2024 non-approval. The chapter appears now as part of a 2025 volume synthesizing psychedelic psychiatry advances.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)[[2]](https://www.sciencedirect.com/bookseries/international-review-of-neurobiology/vol/181/suppl/C)

Key points

PTSD involves re-experiencing trauma, avoidance, hyperarousal, and negative mood changes after events like combat or assault.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
Standard treatments are trauma-focused psychotherapies and medications, but many patients respond poorly.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
MDMA-assisted therapy aids traumatic memory processing in psychotherapy and shows promise beyond PTSD.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
Clinical trials report substantial, lasting PTSD symptom reductions with MDMA therapy.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
FDA granted breakthrough therapy status to MDMA for PTSD in 2017 but denied approval in 2024 over trial flaws like unblinding.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)
Chapter covers psychological/neurobiological mechanisms, methodological issues, and future research needs.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

Details and context

The chapter defines PTSD formally since its DSM-III addition in 1980 and notes its extensive study.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research) It positions MDMA therapy as innovative for resistant cases, building on two decades of development within broader psychedelic research.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

MDMA reportedly enhances psychotherapy by facilitating trauma processing, with trials showing benefits but challenged by blinding difficulties and bias risks.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research) The volume Psychedelics in Psychiatry covers related topics like depression treatments and neuroimaging, framing this work amid growing evidence.[[2]](https://www.sciencedirect.com/bookseries/international-review-of-neurobiology/vol/181/suppl/C)

Key quotes

None sourced from full text.

Why it matters

Psychedelic therapies like MDMA-assisted treatment could expand options for PTSD, a condition affecting many after trauma with limited current remedies. For patients unresponsive to standard care, it offers potential symptom relief, though regulatory hurdles persist. Watch for new trials addressing FDA concerns, which could clarify efficacy and lead to approvals.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

FAQ

Q: What is MDMA-assisted therapy for PTSD?[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

A: It combines 3,4-Methylenedioxymethamphetamine (MDMA) with psychotherapy to enhance traumatic memory processing. Clinical trials have demonstrated substantial and sustained reductions in PTSD symptoms, particularly for treatment-resistant patients. The approach has shown promise over two decades of research.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

Q: Why did the FDA reject MDMA therapy for PTSD in 2024?[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

A: Despite granting breakthrough therapy status in 2017, the FDA cited methodological issues like unblinding and potential expectancy effects in trials. These concerns prevented approval for clinical use. Additional research is required to resolve them.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

Q: What PTSD symptoms does the chapter describe?[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

A: Symptoms include re-experiencing trauma, avoidance behaviors, hyperarousal, and negative changes in cognition and mood. These follow exposure to events like combat, disasters, or assault. PTSD was formally recognized in DSM-III in 1980.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

Q: What does the chapter cover beyond MDMA?[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

A: It explores clinical research on psychedelic-assisted therapies for PTSD generally, including psychological and neurobiological mechanisms. Methodological challenges and future directions are also examined. Evidence supports potential for other psychiatric disorders.[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)

[[1]](https://research.rug.nl/en/publications/post-traumatic-stress-disorder-in-psychedelic-research)[[2]](https://www.sciencedirect.com/bookseries/international-review-of-neurobiology/vol/181/suppl/C)